GENMAB A/S

Alpha Score of 69 reflects moderate overall profile with strong momentum, strong value, moderate quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

Genmab A/S American Depositary Shares represent shares in Genmab A/S, a Copenhagen-based international biotechnology company founded in 1998 that specializes in creating, developing, and commercializing innovative antibody therapeutics to treat cancer and other serious diseases. The company leverages proprietary technologies such as DuoBody, HexaBody, DuoHexaBody, and HexElect to engineer differentiated antibody products. Key marketed therapies include EPKINLY and TEPKINLY for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; Tivdak for recurrent or metastatic cervical cancer; Darzalex, partnered with Johnson & Johnson, established as a standard of care for multiple myeloma; Tepezza for thyroid eye disease with Horizon; Kesimpta for relapsing multiple sclerosis with Novartis; Rybrevant for non-small cell lung cancer with Johnson & Johnson; and Epkinly with AbbVie. Genmab A/S also advances a robust pipeline of antibody-based candidates targeting various solid tumors, B-cell malignancies, ovarian cancer, and other oncologic indications, often through strategic partnerships. This focus positions it as a key player in the oncology and immunology segments of the biotech sector.